FDA Approved Nivolumab for Pediatric Cancer Patients

The therapy is now available for children ages 12 and older when combined with chemotherapy for certain cancer types.

Updated on Oct. 12, 2026 in Cancer

FDA Approved Nivolumab for Pediatric Cancer Patients

The FDA has expanded the use of the immunotherapy agent Nivolumab for pediatric patients aged 12 and older. This treatment, used in combination with chemotherapy, aims to harness the body's immune system to fight cancer.

Why it matters

This approval provides a new treatment pathway for adolescents, potentially reducing the reliance on aggressive interventions like radiation. It addresses a significant need for effective options that minimize long-term health risks for younger patients.

Clinical trials supported the use of this antibody agent in pediatric patients, demonstrating its potential to integrate with traditional chemotherapy. Researchers are still evaluating the long-term outcomes and comparative benefits for this younger population.

The players

FDA

The federal agency responsible for evaluating the safety and efficacy of medical treatments for the public.

Leah Pshedesky

A 17-year-old patient treated at Johns Hopkins All Children's Hospital for stage-four Hodgkin Lymphoma.

Johns Hopkins All Children's Hospital

A pediatric healthcare facility located in St. Petersburg, Florida, where the patient received successful cancer treatment.

The details

Nivolumab functions as an antibody agent that works by training the patient's immune system to identify and attack cancer cells. By combining this immunotherapy with standard chemotherapy, clinicians aim to achieve tumor eradication while potentially avoiding the need for radiation therapy. This approach is designed to mitigate side effects common to traditional treatments, such as kidney damage, liver damage, and risks to future fertility.

In summer 2025, 17-year-old Leah Pshedesky experienced a health scare that led to a stage-four Hodgkin Lymphoma diagnosis.
The FDA approval for pediatric use was reported in October 2026.

Health Landscape

This development represents a shift toward incorporating precision immunotherapy into pediatric oncology standards of care. It follows established trends within the FDA pediatric oncology approval framework for integrating immunotherapy into standard childhood cancer protocols.

For families navigating a pediatric cancer diagnosis, this approval may expand the range of available treatment options worth discussing with an oncologist. It is important to consult a physician to understand how immunotherapy-based regimens compare to traditional protocols and how they might affect long-term health outcomes.

The takeaway

This FDA decision marks an important update in treatment options for pediatric patients requiring systemic therapy. Parents and caregivers should discuss the potential role of immunotherapy with their child's care team to determine if such approaches are appropriate for their specific case.